ID   OHSU-974
AC   CVCL_XX23
SY   OHSU-0974; OHSU974; OHSU-SCC-974
DR   cancercelllines; CVCL_XX23
DR   IARC_TP53; 21669
DR   Wikidata; Q98128333
RX   PubMed=15735012;
RX   PubMed=23613873;
RX   PubMed=25609062;
RX   PubMed=36912284;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser37Profs*7 (c.109delT); ClinVar=VCV001713031; Zygosity=Unspecified (PubMed=23613873).
CC   Caution: TP53 mutation indicated to be at p.Asp41fs (c.121delT) in PubMed=15735012.
CC   Caution: The 8 loci STR profile in PubMed=36912284 supp. table is incorrect and is that of NCI-H1299. The correct and extended (16 loci) profile is shown in this entry thanks to a personal communication of Wakefield, Leslie.
ST   Source(s): PubMed=36912284
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 9
ST   D16S539: 9,11
ST   D18S51: 13
ST   D21S11: 31.2,33.2
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 13
ST   D8S1179: 10,13
ST   FGA: 21,22.2
ST   Penta D: 11,13
ST   Penta E: 11,12
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C125702; Fanconi anemia, complementation group A
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_84; Fanconi anemia
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=15735012; DOI=10.1158/0008-5472.CAN-04-3665;
RA   van Zeeburg H.J.T., Snijders P.J.F., Pals G., Hermsen M.A.J.A.,
RA   Rooimans M.A., Bagby G., Soulier J., Gluckman E., Wennerberg J.,
RA   Leemans C.R., Joenje H., Brakenhoff R.H.;
RT   "Generation and molecular characterization of head and neck squamous
RT   cell lines of Fanconi anemia patients.";
RL   Cancer Res. 65:1271-1276(2005).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=25609062; DOI=10.1158/1078-0432.CCR-14-2616; PMCID=PMC4401632;
RA   Lombardi A.J., Hoskins E.E., Foglesong G.D., Wikenheiser-Brokamp K.A.,
RA   Wiesmuller L., Hanenberg H., Andreassen P.R., Jacobs A.J., Olson S.B.,
RA   Keeble W.W., Hays L.E., Wells S.I.;
RT   "Acquisition of relative interstrand crosslinker resistance and PARP
RT   inhibitor sensitivity in Fanconi anemia head and neck cancers.";
RL   Clin. Cancer Res. 21:1962-1972(2015).
//
RX   PubMed=36912284; DOI=10.1002/ijc.34506;
RA   Nguyen H.T., Tang W.-L., Webster A.L.H., Whiteaker J.R., Chandler C.M.,
RA   Errazquin Ciudad R., Roohollahi K., Fritzke M., Hoskins E.E., Jonlin E.C.,
RA   Wakefield L., Sullivan L.B., Chen E.Y., Dorsman J.C., Brakenhoff R.H.,
RA   Paulovich A.G., Grompe M., Garcia-Escudero R., Wells S.I.,
RA   Smogorzewska A., Monnat R.J. Jr.;
RT   "Fanconi anemia-isogenic head and neck cancer cell line pairs: a basic
RT   and translational science resource.";
RL   Int. J. Cancer 153:183-196(2023).
//